PIK3CA

PIK3CA

A gene on chromosome 3q26.3 that encodes the 110-kDa catalytic subunit of phosphatidylinositol 3-kinase, which uses ATP to phosphorylate phosphatidylinositol, phosphatidylinositol4P and phosphatidylinositol(4,5)P2.
 
Molecular pathology
PIK3CA is oncogenic and been implicated in cervical cancers.
Mentioned in ?
References in periodicals archive ?
Profiled first-in-class therapies include: PIK3CA, EZH2, CD40 and MDM2: - What is the scientific rationale behind these targets?
For non-FIPV-related cancers, which account for the majority of head and neck tumors, they looked for mutations in cancer-related genes that included TP53, PIK3CA, CDKN2A, FBXW7, HRAS, and NRAS.
Also, while both lesions have RAS, PTEN, and PIK3CA mutations, the frequency of mutations is much greater in carcinoma.
Furthermore, three point-mutated PIK3CA protein structures revealed similar binding energies to wortmannin than wildtype PIK3CA.
Moreover, DNA amplified from single CTCs isolated by use of this protocol was analyzed for the presence of mutations in PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit [alpha]) [3] and TP53 (tumor protein p53) genes.
SAN FRANCISCO - Regular aspirin use did not improve outcomes in patients with colorectal cancers with mutations of the PIK3CA gene, according to the largest study yet of aspirin use in this patient population.
79,80) In rare cases of hidradenocarcinomas mutations of TP53, (74,79,81) PIK3CA, (79) and AKT-1 (79) have been documented.
In a study of more than 900 patients with colorectal cancer, taking aspirin improved survival in patients with tumors that contained a mutation in the PIK3CA gene.
The research team has pinpointed the cancer abnormality to a mutation in a gene called PIK3CA that results in a mutant protein, which may be an early cancer switch.
25 New England Journal of Medicine, may lead to standardized testing of colorectal cancer patients for the mutation, in a gene called PIK3CA, to see who would benefit from aspirin use.
By contrast, aspirin had no impact on five-year survival rates among patients without a PIK3CA mutation.
The most commonly mutation in Luminal A cancer is in a gene called PIK3CA, which is also implicated in several other kinds of cancer.